Robert W. Baird Increases Astrana Health (NASDAQ:ASTH) Price Target to $86.00

Astrana Health (NASDAQ:ASTH) had its target price hoisted by equities research analysts at Robert W. Baird from $67.00 to $86.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 105.25% from the company’s current price.

Several other analysts also recently weighed in on ASTH. Truist Financial boosted their target price on shares of Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stifel Nicolaus upped their target price on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. KeyCorp started coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating for the company. TD Cowen assumed coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price objective on the stock. Finally, BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $65.17.

Astrana Health Stock Performance

Shares of ASTH stock opened at $41.90 on Wednesday. Astrana Health has a 12-month low of $32.04 and a 12-month high of $63.20. The business’s fifty day simple moving average is $55.30 and its 200-day simple moving average is $47.68. The company has a current ratio of 1.91, a quick ratio of 1.84 and a debt-to-equity ratio of 0.60. The company has a market cap of $2.06 billion, a PE ratio of 32.23, a PEG ratio of 2.01 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the prior year, the company posted $0.47 EPS. Analysts expect that Astrana Health will post 1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

Institutional investors have recently modified their holdings of the stock. Diamond Hill Capital Management Inc. acquired a new stake in Astrana Health during the third quarter worth about $8,245,000. Summit Global Investments purchased a new stake in Astrana Health in the 3rd quarter worth approximately $753,000. Louisiana State Employees Retirement System acquired a new stake in shares of Astrana Health during the 3rd quarter worth approximately $1,165,000. F M Investments LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $11,738,000. Finally, SteelPeak Wealth LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at $39,398,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.